Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ezeprogind by AlzProtect for Progressive Supranuclear Palsy: Likelihood of Approval
Ezeprogind is under clinical development by AlzProtect and currently in Phase I for Progressive Supranuclear Palsy. According to GlobalData, Phase...